Cellectis SA（CLLS）价格预测CLLSCellectis SA

Alphio's CLLS stock price prediction model matches the current Cellectis SA tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $1.05 (+2.31%). The 1-week path is $1.01 (-1.70%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.

Cellectis SA is not a good buy right now due to its significant financial struggles and negative sentiment surrounding its strategic shift. The current price is $1.035, which is far below the 52-week high of $5.45, indicating a lack of investor confidence. Additionally, the company's forward P/E is 0, suggesting no earnings growth is expected in the near term. The recent downgrade by Barclays, which set a target price of $1.30, reflects concerns about the company's pivot away from CAR-T therapies, further supporting a sell recommendation.

Cellectis SA (CLLS) last closed at $1.03, losing -11.97%. These facts feed the 1-day and 1-week CLLS price prediction above.